Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 13 |
| List of Tables | 12 | 2 |
| List of Figures | 14 | 1 |
| Introduction | 15 | 1 |
| Global Markets Direct Report Coverage | 15 | 1 |
| Clostridium difficile Infections (Clostridium difficile Associated Disease) Overview | 16 | 1 |
| Therapeutics Development | 17 | 2 |
| Pipeline Products for Clostridium difficile Infections (Clostridium difficile Associated Disease) Overview | 17 | 1 |
| Pipeline Products for Clostridium difficile Infections (Clostridium difficile Associated Disease) Comparative Analysis | 18 | 1 |
| Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics under Development by Companies | 19 | 3 |
| Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics under Investigation by Universities/Institutes | 22 | 1 |
| Clostridium difficile Infections (Clostridium difficile Associated Disease) Pipeline Products Glance | 23 | 4 |
| Late Stage Products | 23 | 1 |
| Clinical Stage Products | 24 | 1 |
| Early Stage Products | 25 | 1 |
| Unknown Stage Products | 26 | 1 |
| Clostridium difficile Infections (Clostridium difficile Associated Disease) Products under Development by Companies | 27 | 5 |
| Clostridium difficile Infections (Clostridium difficile Associated Disease) Products under Investigation by Universities/Institutes | 32 | 1 |
| Clostridium difficile Infections (Clostridium difficile Associated Disease) Companies Involved in Therapeutics Development | 33 | 50 |
| Absynth Biologics Limited | 33 | 1 |
| Actelion Ltd | 34 | 1 |
| Adenium Biotech ApS | 35 | 1 |
| AIMM Therapeutics B.V. | 36 | 1 |
| Akthelia Pharmaceuticals Limited | 37 | 1 |
| AmpliPhi Biosciences Corporation | 38 | 1 |
| Angothera GmbH | 39 | 1 |
| Antibiotx ApS | 40 | 1 |
| Appili Therapeutics Inc | 41 | 1 |
| Assembly Biosciences Inc | 42 | 1 |
| AvidBiotics Corp. | 43 | 1 |
| C3 Jian, Inc | 44 | 1 |
| CaroGen Corporation | 45 | 1 |
| Crestone, Inc. | 46 | 1 |
| Da Volterra | 47 | 1 |
| Daiichi Sankyo Company, Limited | 48 | 1 |
| e-Therapeutics Plc | 49 | 1 |
| Evec, Inc. | 50 | 1 |
| GangaGen Inc. | 51 | 1 |
| ImmunoBiology Limited | 52 | 1 |
| Immuron Limited | 53 | 1 |
| Inovio Pharmaceuticals, Inc. | 54 | 1 |
| Integrated BioTherapeutics, Inc. | 55 | 1 |
| MedImmune, LLC | 56 | 1 |
| Merck &Co., Inc. | 57 | 1 |
| MGB Biopharma Limited | 58 | 1 |
| Microbiotix, Inc. | 59 | 1 |
| Micropharm Limited | 60 | 1 |
| Miyarisan Pharmaceutical Company, Ltd | 61 | 1 |
| Morphochem AG | 62 | 1 |
| Nanotherapeutics, Inc. | 63 | 1 |
| Novabiotics Limited | 64 | 1 |
| NovoBiotic Pharmaceuticals, LLC | 65 | 1 |
| Oragenics, Inc. | 66 | 1 |
| Otsuka Holdings Co., Ltd. | 67 | 1 |
| Pfizer Inc. | 68 | 1 |
| Procarta Biosystems Limited | 69 | 1 |
| Prokarium Limited | 70 | 1 |
| Rebiotix Inc. | 71 | 1 |
| Sanofi Pasteur SA | 72 | 1 |
| Second Genome, Inc. | 73 | 1 |
| Seres Therapeutics, Inc. | 74 | 1 |
| Sorrento Therapeutics, Inc. | 75 | 1 |
| Stellar Biotechnologies, Inc. | 76 | 1 |
| Summit Therapeutics Plc | 77 | 1 |
| Synthetic Biologics, Inc. | 78 | 1 |
| Valevia UK Limited | 79 | 1 |
| Valneva SE | 80 | 1 |
| Venenum Biodesign, L.L.C | 81 | 1 |
| XBiotech Inc | 82 | 1 |
| Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Assessment | 83 | 10 |
| Assessment by Monotherapy Products | 83 | 1 |
| Assessment by Combination Products | 84 | 1 |
| Assessment by Target | 85 | 2 |
| Assessment by Mechanism of Action | 87 | 2 |
| Assessment by Route of Administration | 89 | 2 |
| Assessment by Molecule Type | 91 | 2 |
| Drug Profiles | 93 | 110 |
| (miconazole nitrate + nisin) Drug Profile | 93 | 1 |
| ABM-101 Drug Profile | 94 | 1 |
| AKT-10081 Drug Profile | 95 | 1 |
| Ampliphage-004 Drug Profile | 96 | 2 |
| Antibodies for Enterocolitis Drug Profile | 98 | 1 |
| Antibodies to Inhibit Toxin A and Toxin B for Clostridium difficile Infections Drug Profile | 99 | 1 |
| AP-114 Drug Profile | 100 | 1 |
| ATx-401 Drug Profile | 101 | 1 |
| AvR2-V10 Drug Profile | 102 | 2 |
| bezlotoxumab Drug Profile | 104 | 2 |
| Biologic for Clostridium difficile Infections Drug Profile | 106 | 1 |
| Biologics for Clostridium Difficile Infections Drug Profile | 107 | 1 |
| cadazolid Drug Profile | 108 | 2 |
| CBM-588 Drug Profile | 110 | 2 |
| CD-17DL Drug Profile | 112 | 1 |
| Cdiff Snare Drug Profile | 113 | 1 |
| Clostridium difficile (virus like particle) vaccine Drug Profile | 114 | 1 |
| Clostridium difficile vaccine Drug Profile | 115 | 2 |
| Clostridium difficile vaccine Drug Profile | 117 | 1 |
| Clostridium difficile vaccine Drug Profile | 118 | 1 |
| Clostridium difficile vaccine Drug Profile | 119 | 2 |
| clostridium difficile vaccine Drug Profile | 121 | 1 |
| Clostridium difficile vaccine Drug Profile | 122 | 1 |
| Clostridium difficile vaccine Drug Profile | 123 | 1 |
| Clostridium difficile vaccine Drug Profile | 124 | 1 |
| Clostridium difficile vaccine Drug Profile | 125 | 1 |
| CRS-3123 Drug Profile | 126 | 1 |
| DAV-132 Drug Profile | 127 | 1 |
| Drugs for Clostridium difficile Infections Drug Profile | 128 | 1 |
| DS-2969 Drug Profile | 129 | 1 |
| EV-029104 Drug Profile | 130 | 1 |
| EV-029105A Drug Profile | 131 | 1 |
| fidaxomicin Drug Profile | 132 | 6 |
| IMM-529 Drug Profile | 138 | 1 |
| INS-5010 Drug Profile | 139 | 1 |
| INX-201 Drug Profile | 140 | 1 |
| MBX-500 Drug Profile | 141 | 1 |
| MCB-3681 Drug Profile | 142 | 1 |
| MCB-3837 Drug Profile | 143 | 1 |
| metronidazole Drug Profile | 144 | 1 |
| MGBBP-3 Drug Profile | 145 | 3 |
| Monoclonal Antibodies for Clostridium difficile Drug Profile | 148 | 1 |
| Monoclonal Antibodies to Inhibit TcdA and TcdB for Clostridium Difficile and Staphylococcus Aureus Infections Drug Profile | 149 | 1 |
| Monoclonal Antibody for Clostridium Difficile Infections Drug Profile | 150 | 1 |
| Monoclonal Antibody for Clostridium Difficile Infections Drug Profile | 151 | 1 |
| Monoclonal Antibody to Inhibit Clostridium difficile Toxin A and Toxin B for Clostridium Difficile Infections Drug Profile | 152 | 1 |
| NP-432 Drug Profile | 153 | 1 |
| OG-253 Drug Profile | 154 | 2 |
| OG-716 Drug Profile | 156 | 1 |
| OPS-2071 Drug Profile | 157 | 1 |
| OraCAb Drug Profile | 158 | 1 |
| P-100031 Drug Profile | 159 | 1 |
| P-4A Drug Profile | 160 | 1 |
| PF-06425090 Drug Profile | 161 | 2 |
| PolyCAb Drug Profile | 163 | 1 |
| PRO-391 Drug Profile | 164 | 1 |
| ramoplanin Drug Profile | 165 | 1 |
| RBX-2660 Drug Profile | 166 | 3 |
| RBX-7455 Drug Profile | 169 | 1 |
| ribaxamase Drug Profile | 170 | 5 |
| ridinilazole Drug Profile | 175 | 6 |
| SER-109 Drug Profile | 181 | 3 |
| SER-262 Drug Profile | 184 | 1 |
| SHP-01 Drug Profile | 185 | 1 |
| Small Molecule to Inhibit Guanine Riboswitches for MRSA and Clostridium Difficile Infections Drug Profile | 186 | 1 |
| Small Molecules for Clostridium Difficile Infections Drug Profile | 187 | 1 |
| Small Molecules for Clostridium Difficile Infections Drug Profile | 188 | 1 |
| Small Molecules to Inhibit CD Toxin A and Toxin B for Clostridium Difficile Infections Drug Profile | 189 | 1 |
| Small Molecules to Inhibit DNA Synthesis for Infectious Diseases Drug Profile | 190 | 1 |
| Small Molecules to Inhibit Dynamin for Clostridium Difficile Infections Drug Profile | 191 | 1 |
| Small Molecules to Inhibit Metalloprotease for Clostridium difficile Infections Drug Profile | 192 | 1 |
| Small Molecules to Inhibit Toxin A and Toxin B for Clostridium Difficile Infections Drug Profile | 193 | 1 |
| SQ-641 Drug Profile | 194 | 2 |
| SYN-006 Drug Profile | 196 | 1 |
| SYN-007 Drug Profile | 197 | 1 |
| TNP-2092 Drug Profile | 198 | 1 |
| VAL-301 Drug Profile | 199 | 1 |
| VLA-84 Drug Profile | 200 | 3 |
| Clostridium difficile Infections (Clostridium difficile Associated Disease) Dormant Projects | 203 | 3 |
| Clostridium difficile Infections (Clostridium difficile Associated Disease) Discontinued Products | 206 | 1 |
| Clostridium difficile Infections (Clostridium difficile Associated Disease) Product Development Milestones | 207 | 10 |
| Featured News &Press Releases | 207 | 1 |
| Oct 06, 2016: Synthetic Biologics Awarded Research Contract from Centers for Disease Control and Prevention (CDC) for Microbiome Assessment and Intervention to Address Antibiotic Resistance | 207 | 1 |
| Sep 20, 2016: Synthetic Biologics Announces Completion of Enrollment for Phase 2b Proof-of-Concept Clinical Trial for SYN-004 (ribaxamase) for the Prevention of Clostridium Difficile Infection, Antibiotic-Associated Diarrhea and the Emergence of Antib... | 207 | 1 |
| Sep 12, 2016: MGB Biopharma Granted Qualified Infectious Disease Product (QIPD) Designation by U.S. FDA for the Treatment of Clostridium Difficile-associated Diarrhoea (CDAD) for MGB-BP-3 | 208 | 1 |
| Aug 23, 2016: Oragenics Selects New Lantibiotic for Further Development in Clostridium difficile Infections | 209 | 1 |
| Jul 29, 2016: Seres Therapeutics Announces Interim Results from SER-109 Phase 2 ECOSPOR Study in Multiply Recurrent Clostridium difficile Infection | 209 | 1 |
| Jul 25, 2016: FDA Grants QIDP and Fast Track Designations to MCB3837, Morphochems Novel Intravenous Antibacterial to Treat C. Difficile Infections | 210 | 1 |
| Jul 25, 2016: VALNEVA Announces Successful Completion of Phase II for Clostridium Difficile Vaccine Candidate | 211 | 1 |
| Jul 21, 2016: Merck Provides Regulatory Update on Biologics Licensing Application for Investigational Agent Bezlotoxumab | 212 | 1 |
| Jul 12, 2016: Synthetic Biologics Announces Granting of European and U.S. Composition of Matter Patents for Ribaxamase | 212 | 1 |
| Jul 07, 2016: Synthetic Biologics Receives USAN Approval for Generic Name Ribaxamase for Phase 2 Drug Candidate SYN-004 | 213 | 1 |
| Jul 07, 2016: Seres Therapeutics Announces Initiation of a Phase 1b Clinical Trial of SER-262 for Primary Clostridium difficile Infection | 214 | 1 |
| Jul 05, 2016: Da Volterra Presented Highly Convincing Results of Pre-clinical Studies at ASM 2016 : DAV131 Prevents CDI | 214 | 1 |
| Jun 22, 2016: Morphochem s Investigational New Drug (IND) Application Accepted by the FDA | 214 | 1 |
| Jun 20, 2016: Summits Ridinilazole Preserves Microbiome During Treatment of C. Difficile Infection | 215 | 1 |
| Jun 20, 2016: Seres Therapeutics Presents New Data on SER-109 at ASM Microbe 2016 | 216 | 1 |
| Appendix | 217 | 2 |
| Methodology | 217 | 1 |
| Coverage | 217 | 1 |
| Secondary Research | 217 | 1 |
| Primary Research | 217 | 1 |
| Expert Panel Validation | 217 | 1 |
| Contact Us | 217 | 1 |
| Disclaimer | 218 | 1 |